| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 80 | 13.7x | 17.8x | Top tier | |
Growth | 49 | 5.0% | 7.1% | Around median | |
Quality | 92 | 14.3% | 4.5% | Top tier | |
Safety | 67 | 1.6x | 2.6x | Top tier | |
Capital Return | 47 | 1.82% | 2.12% | Around median | |
Momentum | 46 | 30.2% | 2.9% | Around median | |
Sentiment | 87 | 10 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
GSK plc is a pharmaceutical company focused on developing and marketing new medicines, generating revenue from its pharmaceutical portfolio. The July 28, 2026 announcement of £400 million allocated to research and development in Britain, including a new center in Cambridge, underscores that expanding the drug pipeline and accelerating its transition from the laboratory to the market are central to the company’s growth model.
In fiscal year 2025, revenue increased to $32.7 billion from $31.4 billion in fiscal year 2024, or by approximately 4.1%. Gross profit reached $23.6 billion versus $22.3 billion, equivalent to a gross margin of approximately 72.2% compared with approximately 71.0%, while net income doubled to $6.3 billion from $3.0 billion and earnings per share increased to 1.388 from 0.622. The data do not include a segment breakdown of fiscal year 2025 revenue, so the contribution of each business activity to sales cannot be determined without going beyond the available information.
The average analyst price target is $52.45 with a consensus rating of Neutral, while the target range extends from $35.25 to $85. The average is approximately 15% below the 52-week range high of $61.70, while the lowest target is below the range low of $38.63 and the highest target is above its high, reflecting broad disagreement over fair value despite the improvement in fiscal year 2025 earnings.
Figures in the text are as of 2026-08-26; the live price is shown at the top of the page.
GSK recorded revenue of $32.7 billion in fiscal year 2025, compared with $31.4 billion in fiscal year 2024. Gross profit increased to $23.6 billion, equivalent to a calculated gross margin of approximately 72.2%. Net income also reached $6.3 billion and earnings per share were 1.388, compared with net income of $3.0 billion and earnings per share of 0.622 in the previous year.
GSK announced on July 28, 2026 an investment of £400 million in Britain over three years. The plan includes establishing a new research and development center in Cambridge. The center aims to accelerate the transition of medicines from the laboratory to the market, but the data do not specify a financial return or particular products associated with the plan.
The analyst consensus on GSK is Neutral, so it does not represent an explicit Buy stance. The average price target is $52.45, compared with a high target of $85 and a low target of $35.25. This wide range reflects substantial disagreement among analysts regarding fair value and the earnings outlook.
Automated analysis for informational purposes only — not investment advice.
Revenue increased from $24.7 billion in fiscal year 2021 to $29.3 billion in fiscal year 2022. It then rose to $30.3 billion in fiscal year 2023 and $31.4 billion in fiscal year 2024. It reached $32.7 billion in fiscal year 2025, meaning that each year in this series recorded higher revenue than the preceding year.
The most prominent risk is the volatility of net income, which reached $15.6 billion in fiscal year 2022 before declining to $5.3 billion in fiscal year 2023 and $3.0 billion in fiscal year 2024. Despite recovering to $6.3 billion in fiscal year 2025, it remained far below the fiscal year 2022 level. Fiscal year 2025 revenue growth was also limited to approximately 4.1%, increasing the importance of sustaining margins and generating returns from the £400 million research and development investment.
